Policies, codes and standards
We believe how we deliver is just as important as what we deliver.
To achieve our mission to help people do more, feel better and live longer, we rely those inside and outside our company to work responsibly and adhere to set standards that reflect our company ethos and values.
Our values are enforced through our Company Code of Conduct, robust compliance processes and adherence to peak body standards as set out by the Medicines Australia Code of Conduct and the Australian Self Medication Industry standards.
Read our global policies for more information on the industry codes and standards which GSK operates under.
Submissions to government:
GSK Australia supports the Australian Government’s implementation of a new measure to embed pharmacists
in residential aged care homes to improve medication management and safety. We call on the Government to
expand this role beyond medicine management to include the delivery of National Immunisation Program and
private market vaccinations.
Australian HTA frameworks have been slow to adapt to emerging technologies and issues, seeing Australia become unaligned with international best practice, especially on access to preventative health. We now have a unique opportunity to bring the system into the 21st century and improve its processes for the betterment of Australian patients.
GSK Australia welcomes the opportunity to have further input into the Pharmaceutical Benefits Advisory Committee (PBAC)’s review of the base discount rate. We support the Medicines Australia submission to the PBAC on the Base Case Discount Rate1 calling for the discount rate to be lowered to 1.5%. As stated in the Medicines Australia submission, a reduced discount rate would align with international best practice, and better reflect the value of preventative medicines to the community, health system and economy.
GSK Australia supports Australia’s draft National Science and Research Priorities proposed by the Government. We applaud the prioritisation of “healthy and thriving communities" and recognition of the important role preventive health has in achieving objectives and aims associated with it. Our submission highlights actions to strengthen the suggested Priorities by recognising that investment is essential for Australia to lead on preventive health, value of clinical trials to Australia, and antimicrobial resistance as an area of critical research.
As a long-standing partner in the National Medicines Policy (NMP), GSK Australia recognises the policy’s importance and support its overarching aim to deliver positive health outcomes for all Australians through their access to and appropriate use of medicines. We welcomed the invitation to have input into the Review of the NMP.
GSK Australia welcomes the invitation to comment on the Health Technology Assessment (HTA) Policy and Methods Review Options Paper. The Review and its extensive consultation process are critical to delivering timely access to innovative medicines and vaccines for Australian patients. However, the Options proposed in this paper do not currently maximise this opportunity to bring the health system into the 21st century and improve HTA for the betterment of Australian patients.